Home › Cancro alla prostata › California › Orange
Studi clinici su Cancro alla prostata a Orange, CA
14 studi su Cancro alla prostata cercano partecipanti presso sedi a Orange e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial
In reclutamentoFase 3
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial
In reclutamentoFase 2
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
In reclutamentoFase 3
- University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0040), Orange
A Study of Xaluritamig Plus Abiraterone Versus Investigator's Choice in Participants With Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer
In reclutamentoFase 3
- University of California Irvine, Orange
Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC
In reclutamentoFase 3
- Univ Cali Irvine ALS Neuromuscular, Orange
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)
In reclutamentoFase 3
- University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 0006), Orange
Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
In reclutamentoFase 3
- UC Irvine Health, Orange
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With High Risk Prostate Cancer
In reclutamentoFase 3
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
In reclutamentoFase 1
- UCI Health Chao Family Comprehensive Cancer Center, Orange
Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response
In reclutamentoFase 3
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
In reclutamentoFase 2
- Chao Family Comprehensive Cancer Center, University of California Irvine, Orange
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of INV-9956 in Adult Patients With Advanced Metastatic Castration Resistant Prostate Cancer
In reclutamentoFase 1/2
- UC Irvine Medical Center, Orange
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
In reclutamentoFase 4
- St. Joseph Hospital, Orange
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
In reclutamentoStudio osservazionale
- Massive Bio SYNERGY-AI site, Orange
Studi su Cancro alla prostata in altre città
- New York City, NY103 studi
- Houston, TX76 studi
- Los Angeles, CA61 studi
- Boston, MA59 studi
- St. Louis, MO46 studi
- Chicago, IL45 studi
- San Francisco, CA45 studi
- Philadelphia, PA44 studi
- Baltimore, MD43 studi
- Nashville, TN42 studi
- Seattle, WA42 studi
- Washington, DC38 studi
Altri studi a Orange
- Cancro del polmone non a piccole cellule25 studi
- Cancro metastatico20 studi
- Cancro colorettale16 studi
- Cancro ovarico16 studi
- Cancro pancreatico15 studi
- Cancro al seno14 studi
- Cancro ai polmoni14 studi
- Cancro al fegato (carcinoma epatocellulare)14 studi
- Melanoma14 studi
- Leucemia mieloide acuta13 studi
- Cancro (tutti i tipi)13 studi
- Cancro dello stomaco13 studi
Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.